基于微生物组的治疗方法在减少和预防抗菌素耐药生物定植中的作用

IF 2.5 3区 生物学 Q3 MICROBIOLOGY Anaerobe Pub Date : 2023-10-01 DOI:10.1016/j.anaerobe.2023.102772
Armaghan-e-Rehman Mansoor, Caroline A. O'Neil, Jennie H. Kwon
{"title":"基于微生物组的治疗方法在减少和预防抗菌素耐药生物定植中的作用","authors":"Armaghan-e-Rehman Mansoor,&nbsp;Caroline A. O'Neil,&nbsp;Jennie H. Kwon","doi":"10.1016/j.anaerobe.2023.102772","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>The gut is host to a diverse array of microbiota that constitute a complex ecological system crucial to </span>human physiology<span>. Disruptors to the normal host microbiota, such as antimicrobials, can cause a loss of species diversity in the gut, reducing its ability to resist colonization by invading pathogens<span><span> and potentially leading to colonization with antimicrobial resistant organisms (AROs). ARO negatively impact gut health by disrupting the usual heterogeneity of gut microbiota and have the potential to cause </span>systemic disease<span>. In recent years, fecal microbiota transplantation (FMT) has been increasingly explored in the management of specific disease states such as </span></span></span></span><span><em>Clostridioides difficile</em></span> infection (CDI). Promising data from management of CDI has led to considerable interest in understanding the role of therapeutics to restore the gut microbiota to a healthy state. This review aims to discuss key studies that highlight the current landscape, and explore existing clinical evidence, for the use of FMT and microbiome-based therapeutics in combating intestinal colonization with ARO. We also explore potential future directions of such therapeutics and discuss unaddressed needs in this field that merit further investigation.</p></div>","PeriodicalId":8050,"journal":{"name":"Anaerobe","volume":"83 ","pages":"Article 102772"},"PeriodicalIF":2.5000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The role of microbiome-based therapeutics for the reduction and prevention of antimicrobial-resistant organism colonization\",\"authors\":\"Armaghan-e-Rehman Mansoor,&nbsp;Caroline A. O'Neil,&nbsp;Jennie H. Kwon\",\"doi\":\"10.1016/j.anaerobe.2023.102772\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span>The gut is host to a diverse array of microbiota that constitute a complex ecological system crucial to </span>human physiology<span>. Disruptors to the normal host microbiota, such as antimicrobials, can cause a loss of species diversity in the gut, reducing its ability to resist colonization by invading pathogens<span><span> and potentially leading to colonization with antimicrobial resistant organisms (AROs). ARO negatively impact gut health by disrupting the usual heterogeneity of gut microbiota and have the potential to cause </span>systemic disease<span>. In recent years, fecal microbiota transplantation (FMT) has been increasingly explored in the management of specific disease states such as </span></span></span></span><span><em>Clostridioides difficile</em></span> infection (CDI). Promising data from management of CDI has led to considerable interest in understanding the role of therapeutics to restore the gut microbiota to a healthy state. This review aims to discuss key studies that highlight the current landscape, and explore existing clinical evidence, for the use of FMT and microbiome-based therapeutics in combating intestinal colonization with ARO. We also explore potential future directions of such therapeutics and discuss unaddressed needs in this field that merit further investigation.</p></div>\",\"PeriodicalId\":8050,\"journal\":{\"name\":\"Anaerobe\",\"volume\":\"83 \",\"pages\":\"Article 102772\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anaerobe\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1075996423000811\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anaerobe","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1075996423000811","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

肠道是多种微生物群的宿主,这些微生物群构成了一个对人类生理至关重要的复杂生态系统。正常宿主微生物群的破坏者,如抗菌药物,会导致肠道物种多样性的丧失,降低其抵抗入侵病原体定植的能力,并可能导致抗微生物微生物(ARO)的定植。ARO通过破坏肠道微生物群的常见异质性对肠道健康产生负面影响,并有可能导致系统性疾病。近年来,粪便微生物群移植(FMT)在管理艰难梭菌感染(CDI)等特定疾病状态方面得到了越来越多的探索。来自CDI管理的有希望的数据引起了人们对理解治疗方法在将肠道微生物群恢复到健康状态方面的作用的极大兴趣。这篇综述旨在讨论强调当前形势的关键研究,并探索现有的临床证据,以使用FMT和基于微生物组的治疗方法对抗ARO的肠道定植。我们还探索了这种疗法未来的潜在方向,并讨论了该领域值得进一步研究的未解决需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The role of microbiome-based therapeutics for the reduction and prevention of antimicrobial-resistant organism colonization

The gut is host to a diverse array of microbiota that constitute a complex ecological system crucial to human physiology. Disruptors to the normal host microbiota, such as antimicrobials, can cause a loss of species diversity in the gut, reducing its ability to resist colonization by invading pathogens and potentially leading to colonization with antimicrobial resistant organisms (AROs). ARO negatively impact gut health by disrupting the usual heterogeneity of gut microbiota and have the potential to cause systemic disease. In recent years, fecal microbiota transplantation (FMT) has been increasingly explored in the management of specific disease states such as Clostridioides difficile infection (CDI). Promising data from management of CDI has led to considerable interest in understanding the role of therapeutics to restore the gut microbiota to a healthy state. This review aims to discuss key studies that highlight the current landscape, and explore existing clinical evidence, for the use of FMT and microbiome-based therapeutics in combating intestinal colonization with ARO. We also explore potential future directions of such therapeutics and discuss unaddressed needs in this field that merit further investigation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
相关文献
二甲双胍通过HDAC6和FoxO3a转录调控肌肉生长抑制素诱导肌肉萎缩
IF 8.9 1区 医学Journal of Cachexia, Sarcopenia and MusclePub Date : 2021-11-02 DOI: 10.1002/jcsm.12833
Min Ju Kang, Ji Wook Moon, Jung Ok Lee, Ji Hae Kim, Eun Jeong Jung, Su Jin Kim, Joo Yeon Oh, Sang Woo Wu, Pu Reum Lee, Sun Hwa Park, Hyeon Soo Kim
具有疾病敏感单倍型的非亲属供体脐带血移植后的1型糖尿病
IF 3.2 3区 医学Journal of Diabetes InvestigationPub Date : 2022-11-02 DOI: 10.1111/jdi.13939
Kensuke Matsumoto, Taisuke Matsuyama, Ritsu Sumiyoshi, Matsuo Takuji, Tadashi Yamamoto, Ryosuke Shirasaki, Haruko Tashiro
封面:蛋白质组学分析确定IRSp53和fastin是PRV输出和直接细胞-细胞传播的关键
IF 3.4 4区 生物学ProteomicsPub Date : 2019-12-02 DOI: 10.1002/pmic.201970201
Fei-Long Yu, Huan Miao, Jinjin Xia, Fan Jia, Huadong Wang, Fuqiang Xu, Lin Guo
来源期刊
Anaerobe
Anaerobe 生物-微生物学
CiteScore
5.20
自引率
8.70%
发文量
137
审稿时长
76 days
期刊介绍: Anaerobe is essential reading for those who wish to remain at the forefront of discoveries relating to life processes of strictly anaerobes. The journal is multi-disciplinary, and provides a unique forum for those investigating anaerobic organisms that cause infections in humans and animals, as well as anaerobes that play roles in microbiomes or environmental processes. Anaerobe publishes reviews, mini reviews, original research articles, notes and case reports. Relevant topics fall into the broad categories of anaerobes in human and animal diseases, anaerobes in the microbiome, anaerobes in the environment, diagnosis of anaerobes in clinical microbiology laboratories, molecular biology, genetics, pathogenesis, toxins and antibiotic susceptibility of anaerobic bacteria.
期刊最新文献
Regulatory networks: Linking toxin production and sporulation in Clostridioides difficile Veillonella orientalis sp. nov., an anaerobic Gram-stain-negaitve coccus isolated from saliva of a Thai child Chitin promotes equol production via n-acetylglucosamine in human fecal cultures Clostridioides difficile hypervirulent strain ST1 isolated from clinical stool specimens obtained from three Provinces in South Africa New insights into the factors influencing methanogenic pathways in anaerobic digesters
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1